(Q49577334)

English

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials.

scientific article published on 30 January 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials. (English)

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Sjögren's syndrome

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

Valérie Devauchelle-Pensec

4

object named as

Valérie Devauchelle-Pensec

1 reference

Europe PubMed Central

15 June 2018

Caroline Gordon

17

object named as

Caroline Gordon

1 reference

Europe PubMed Central

15 June 2018

Xavier Mariette

6

object named as

Xavier Mariette

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

author name string

Jacques-Eric Gottenberg

1

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Thomas Dörner

2

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Hendrika Bootsma

3

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Simon J Bowman

5

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Holger Bartz

7

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Marga Oortgiesen

8

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Anthony Shock

9

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Willem Koetse

10

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Catrinel Galateanu

11

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Sabine Bongardt

12

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

William A Wegener

13

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

David M Goldenberg

14

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Guy Meno-Tetang

15

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Gordana Kosutic

16

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

publication date

12 April 2018

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Arthritis & Rheumatology

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

70

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

5

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

763-773

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Multiple Roles for B-Lymphocytes in Sjogren's Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Update on the immunobiology of Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

The epidemiology of Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

The pathogenesis of systemic lupus erythematosus—an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Pathogenesis of Sjögren's syndrome and therapeutic consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Significance of B cells and B cell clonality in Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Numerical scoring for the BILAG-2004 index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

16 June 2018

Treatment of primary Sjögren syndrome with rituximab: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947119

14 August 2018

Systemic lupus erythematosus disease activity index 2000

1 reference

https://pubmed.ncbi.nlm.nih.gov/29381843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/29381843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/29381843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sjögren's syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/29381843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

1 reference

https://pubmed.ncbi.nlm.nih.gov/29381843

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.40425

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5947119

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49577334&oldid=1967451796"